Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 31, 2020

EGFR and BRAF Inhibition Effective in BRAF-Mutant CRC

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
J. Clin. Oncol 2020 Dec 23;[EPub Ahead of Print], S Kopetz, KA Guthrie, VK Morris, HJ Lenz, AM Magliocco, D Maru, Y Yan, R Lanman, G Manyam, DS Hong, A Sorokin, CE Atreya, LA Diaz, C Allegra, KP Raghav, SE Wang, CH Lieu, SL McDonough, PA Philip, HS Hochster

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading